Supratherapeutic oseltamivir levels during continuous dialysis: An expected risk

Intensive Care Medicine

Volumn 37, Issue 2, 2011, Pages 371-

  Eschenauer, Gregory A ^a   Lam, Simon W ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; OSELTAMIVIR;

AREA UNDER THE CURVE; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICAL ILLNESS; DISEASE SEVERITY; DRUG TOLERABILITY; EXTRACORPOREAL OXYGENATION; GLOMERULUS FILTRATION; HUMAN; INFLUENZA A (H1N1); KIDNEY CLEARANCE; LETTER; RISK FACTOR;

ANTIVIRAL AGENTS; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; OSELTAMIVIR; RENAL DIALYSIS; RISK ASSESSMENT;

EID: 79953814135     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-010-2080-5     Document Type: Letter

References (5)

1. Lemaitre F, Luyt CE, Roullet-Renoleau F, Nieszkowska A, Zahr N, Fernandez C, Farinotti R, Combes A (2010) Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation. Intensive Care Med 36:1273-1274
2. He G, Massarella J, Ward P (1999) Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37:471-484 (Pubitemid 30032251)
3. Gruber PC, Tian Q, Gomersall CD, Joynt GM, Choi GY (2007) An in vitro study of the elimination of oseltamivir carboxylate by haemofiltration. Int J Antimicrob Agents 30:95-97 (Pubitemid 46874900)
4. Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J (2009) Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 37:2268-2282
5. Buck ML (2003) Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 42:403-417